Antibacterial Activity of Lefamulin against Pathogens Most Commonly Causing Community-Acquired Bacterial Pneumonia: SENTRY Antimicrobial Surveillance Program (2015–2016)

Antzeko izenburuak

• 1365. In Vitro Activity of Lefamulin (LEF) Against Bacterial Pathogens Causing Community-Acquired Bacterial Pneumonia (CABP): SENTRY Surveillance 2016 Results From Asia-Pacific (APAC) and Latin America (LA)
  nork: Paukner, Susanne, et al.
  Argitaratua: (2018)
• Low Prevalence of Gram-Positive Isolates Showing Elevated Lefamulin MIC Results during the SENTRY Surveillance Program for 2015–2016 and Characterization of Resistance Mechanisms
  nork: Mendes, Rodrigo E., et al.
  Argitaratua: (2019)
• 1353. In Vitro Activity of Lefamulin (LEF) Against Bacterial Pathogens Commonly Causing Community-Acquired Bacterial Pneumonia (CABP): 2016 SENTRY Data From the United States
  nork: Paukner, Susanne, et al.
  Argitaratua: (2018)
• In Vitro Activity of Lefamulin Against a Global Collection of Bacterial Pathogens Commonly Causing Community-Acquired Bacterial Pneumonia (CABP, SENTRY 2015)
  nork: Paukner, Susanne, et al.
  Argitaratua: (2017)
• 703. In Vitro Activity of Lefamulin Against Bacterial Pathogens Causing Community-Acquired Bacterial Pneumonia (CABP): SENTRY Surveillance 2017–2018 Results From the United States (US)
  nork: Sader, Helio S, et al.
  Argitaratua: (2019)